GIAPREZA
Commercial- Indications
- Septic shock, Distributive shock
Company intelligence / Profile preview
La Jolla Pharmaceutical Company commercializes GIAPREZA (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) for treating complicated intra-abdominal infections. The company reported $10.4 million in net product sales for Q1 2022, up 21% from the same period in 2021[3].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on La Jolla Pharmaceutical Company.